Contents

1 Extrapolation of Preclinical Data into Clinical Reality – Translational Science
   T. Singer .................................................. 1

2 Smarter Candidate Selection – Utilizing Microdosing in Exploratory Clinical Studies
   P. Buchan ................................................. 7

3 The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
   J. Kuhlmann ................................................. 29

4 Using Exposure – Response and Biomarkers to Streamline Early Drug Development
   J. Venitz .................................................. 47

5 Experiences with Dose Finding in Patients in Early Drug Development:
   The Use of Biomarkers in Early Decision Making

6 Genotype and Phenotype Relationship in Drug Metabolism
XII Contents

7 Clinical Trials in Elderly Patients
   S.H.D. Jackson ......................................................... 101

8 Dose Finding in Pediatric Patients
   G. Henze ................................................................. 111

9 Integration of Pediatric Aspects
   into the General Drug Development Process
   K. Rose ................................................................. 123

10 Current Stumbling Blocks in Oncology Drug Development
    C.D. Gimmi ............................................................ 135

11 Exploratory IND: A New Regulatory Strategy
   for Early Clinical Drug Development in the United States
   N. Sarapa ............................................................. 151

12 Ethnic Aspects of Cancer Trials in Asia
    T.W.T. Leung .......................................................... 165

13 Evaluation of the Effect on Cardiac Repolarization
   (QTc Interval) of Oncologic Drugs
    J. Morganroth ..................................................... 171

14 The Role of PET Scanning
   in Determining Pharmacoselective Doses
   in Oncology Drug Development
    P. Price ............................................................... 185

15 Biometrical Aspects of Drug Development
    D. Machin, S-B. Tan ............................................... 195

16 Preventing Postmarketing Changes in Recommended Doses
   and Marketing Withdrawals
    C. Peck ............................................................... 209

Previous Volumes Published in This Series ..................... 217
Appropriate Dose Selection - How to Optimize Clinical Drug Development
Venitz, J.; Sittner, W. (Eds.)
2007, XVI, 216 p., Hardcover
ISBN: 978-3-540-27867-2